Respiratory

Ascletis Pharma receives FDA approval for trial of RSV infection therapy

Ascletis Pharma has received approval from the US Food and Drug Administration (FDA) to conduct a Phase IIa clinical trial…

Pliant reports trial data of bexotegrast for idiopathic pulmonary fibrosis

Pliant Therapeutics has reported preliminary results from the 320mg dose group of the INTEGRIS-IPF Phase IIa clinical trial of bexotegrast…

Moderna reports positive data from RSV vaccine trial

Moderna has reported positive data from the Phase III ConquerRSV trial of its investigational mRNA vaccine, mRNA-1345, targeting respiratory syncytial…

Adaptive Phage begins subject dosing in cystic fibrosis therapy trial

Biotechnology company Adaptive Phage Therapeutics has dosed the first participant in the PHAGE clinical trial of bacteriophage therapy in cystic…

Bavarian Nordic completes subject enrolment in RSV vaccine trial

Bavarian Nordic has completed the participant enrolment in the Phase III clinical trial of its MVA-BN respiratory syncytial virus (RSV)…

Pipeline Moves: AbbVie and Janssen terminate Phase III lymphoma trial, approval prospects plummet

This week on Pipeline Moves, we look into the terminations of two oncology clinical trials. We also review the positive…

SpliSense begins Phase I/II trial of SPL84 for cystic fibrosis

SpliSense has commenced a Phase I/II clinical trial of its lead anti sense oligonucleotide (ASO) product, SPL84, to treat patients…

SpectrumX prepares for clinical development of respiratory drug candidate

Healthcare and pharmaceutical firm SpectrumX has announced that it is prepared to proceed with the clinical development of SPX-001, its…

Redx Pharma previews development plans for idiopathic pulmonary fibrosis and fibrostenotic Crohn’s disease

Redx Pharma plans to conduct a Phase IIb study further investigating RXC007 in idiopathic pulmonary fibrosis (IPF), says Dr Jane…

Pipeline Moves: Novartis resumes Phase II myelofibrosis trial, oncology trial completions

This week on Pipeline Moves, we look into a resumption of a Phase II trial in myelofibrosis which was previously…